Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

Leerink Partnrs issued their Q1 2025 earnings per share estimates for Mind Medicine (MindMed) in a report released on ...

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

Evercore ISI initiated coverage on MindMed shares (NASDAQ:MNMD) with an Outperform rating and a price target of $23.00, well ...

REGENXBIO Inc. today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at ...

Rad AI, one of the fastest growing healthcare AI companies and the first to successfully commercialize a generative AI ...

MindMed could have some significant political tailwinds on the near horizon. MindMed stock is surging today following a recent report from a Minnesota-based task force that urged the ...